Key result
Picotamide showed a borderline reduction in the sum of major and minor cardiovascular events compared to placebo in patients with peripheral vascular disease (risk reduction 18.9%; p=0.056).
Why the study?
Does picotamide reduce cardiovascular complications in patients with peripheral vascular disease?
RCT (n=2,304)
Double-blind
randomly allocated
Does picotamide reduce cardiovascular complications in patients with peripheral vascular disease?
Effect estimate: risk reduction 18.9%
Absolute Event Rate: 10.6% vs 13.1%
p-value: p=0.056
Picotamide may reduce overall cardiovascular complications in patients with peripheral vascular disease, though its effect on major events appears low.
No takes yet. Share an insight, caveat, or question.
Borderline event reduction suggests possible benefit in peripheral vascular disease; leaves open efficacy on major endpoints.
Balsano et al. (1993) conducted an RCT in peripheral vascular disease (PVD) (n=2,304). picotamide vs. placebo was evaluated on sum of major and minor cardiovascular events (intention-to-treat) (risk reduction 18.9%, p=0.056). Picotamide showed a borderline reduction in the sum of major and minor cardiovascular events compared to placebo in patients with peripheral vascular disease (risk reduction 18.9%; p=0.056).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: